How to Get Rezdiffra (Resmetirom) in Maine

What Is Rezdiffra and Why Does It Matter for Maine Patients?

Rezdiffra (resmetirom) is the first FDA-approved oral medication for MASH with moderate-to-advanced hepatic fibrosis (stages F2-F3), filling a gap that left roughly 6.5 million Americans with no approved pharmacotherapy before March 2024. The drug is a thyroid hormone receptor beta (THR-β) selective agonist that reduces liver fat and reverses fibrotic scarring without the systemic thyroid effects associated with nonselective thyroid receptor activation.

Maine has a notable burden of liver disease. Data from the CDC's National Vital Statistics System show chronic liver disease ranks among the top 12 causes of death in the state. Obesity prevalence in Maine sits near 33%, according to the CDC's Behavioral Risk Factor Surveillance System, and obesity is the primary driver of MASH progression. Prior to resmetirom's approval, Maine clinicians managed MASH exclusively through lifestyle modification and off-label vitamin E or pioglitazone. Rezdiffra changed that calculus.

In the MAESTRO-NASH phase 3 trial (N=966), resmetirom 100 mg achieved MASH resolution without worsening of fibrosis in 29.9% of patients at 52 weeks, compared with 9.7% on placebo. The 80 mg arm achieved 25.9% resolution. Fibrosis improvement by at least one stage occurred in 25.9% of the 100 mg group versus 14.2% on placebo [1]. These results led the FDA to grant accelerated approval on March 14, 2024, under the Rezdiffra prescribing label.

Who Can Prescribe Rezdiffra in Maine?

Any Maine-licensed prescriber with independent prescriptive authority can write a Rezdiffra prescription, including MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs). Maine is a full-practice-authority state for NPs under Maine Revised Statutes Title 32, Chapter 31, meaning NPs do not require a collaborating physician to prescribe schedule-unscheduled medications like resmetirom.

Hepatologists and gastroenterologists are the most common prescribers given their familiarity with liver fibrosis staging. Primary care physicians may also prescribe Rezdiffra if they have documented fibrosis staging and confirmed a MASH diagnosis. Some payers, including Maine Medicaid, may require the prescriber to demonstrate specialty involvement or a specialty consultation note as part of the prior authorization packet.

The practical barrier is not licensure. It is awareness. A 2024 survey published in Hepatology Communications found that fewer than 40% of primary care providers felt confident diagnosing MASH fibrosis stage, which can delay appropriate referrals.

Telehealth Access to Rezdiffra in Maine

Maine permits telehealth prescribing of resmetirom under existing state telehealth parity laws. Patients do not need an initial in-person visit before receiving a prescription via telehealth for non-controlled substances. Rezdiffra is not a controlled substance.

Telehealth platforms specializing in metabolic liver disease can connect Maine patients with hepatologists or endocrinologists licensed in the state. The visit typically involves reviewing prior imaging, lab results, and fibrosis staging documentation. If a patient has not yet undergone fibrosis assessment, the telehealth provider can order a FibroScan at a local Maine facility (available at MaineHealth, Northern Light Health, and several independent imaging centers) and then complete the prescribing visit once results are available.

For rural patients in Aroostook County, Washington County, or other underserved regions, telehealth eliminates a drive that can exceed 3 hours each way to the nearest hepatology practice in Portland or Bangor. The American Association for the Study of Liver Diseases (AASLD) has endorsed telemedicine as a tool to expand hepatology access in states with geographic barriers.

A telehealth encounter for Rezdiffra prescribing usually takes 20 to 30 minutes. The provider will verify MASH diagnosis, confirm fibrosis stage F2 or F3, review contraindications, and send the electronic prescription to a specialty or compounding pharmacy in Maine.

What Labs and Tests Are Required Before Starting Rezdiffra?

Prescribers must confirm the diagnosis and rule out contraindications before writing a Rezdiffra prescription. The required workup includes several components.

Liver fibrosis staging is the most important prerequisite. The FDA-approved label specifies Rezdiffra for patients with MASH and moderate-to-advanced fibrosis (F2-F3). Staging can be performed via transient elastography (FibroScan), magnetic resonance elastography (MRE), or liver biopsy. FibroScan is the most accessible option in Maine, with devices at MaineHealth Medical Center in Portland and Northern Light Eastern Maine Medical Center in Bangor. A FibroScan score of 8.0-13.0 kPa generally corresponds to F2-F3 fibrosis.

Liver function tests (ALT, AST, GGT, alkaline phosphatase, bilirubin, albumin) establish baseline hepatic function. Resmetirom can reduce ALT levels; in MAESTRO-NASH, ALT decreased by a median of 36% in the 100 mg group at 24 weeks [1].

Thyroid function panel (TSH, free T4) is recommended because resmetirom acts on thyroid hormone receptors. Patients with decompensated hypothyroidism should have thyroid levels optimized before initiation. The THR-β selectivity of resmetirom minimizes cardiac and bone effects associated with THR-α activation, but baseline thyroid assessment remains standard practice per Endocrine Society guidance.

Lipid panel provides another baseline metric. Resmetirom reduces LDL cholesterol by approximately 14% and triglycerides by approximately 20%, effects confirmed in the phase 3 data published in the New England Journal of Medicine [1]. Payers may request lipid results as supporting evidence of metabolic syndrome.

Complete blood count and INR help rule out advanced cirrhosis (F4), which falls outside the approved indication. Thrombocytopenia (platelets <150,000) can signal portal hypertension.

A hepatologist quoted in the AASLD 2024 practice guidance stated: "The minimum diagnostic package for Rezdiffra candidacy is a confirmed fibrosis stage by elastography or biopsy, baseline hepatic panel, and thyroid function. Without fibrosis staging, the prior authorization will not go through."

Maine Medicaid Coverage and Prior Authorization

Maine Medicaid (MaineCare) covers Rezdiffra with prior authorization. The prior authorization process requires specific documentation, and missing even one element can trigger a denial.

Required documentation for MaineCare PA includes:

• Confirmed MASH diagnosis (ICD-10: K75.81)
• Fibrosis stage F2 or F3 documented by elastography, MRE, or biopsy report
• Baseline liver function tests within the past 90 days
• Body weight (to determine 80 mg vs. 100 mg dosing: 80 mg for patients <100 kg, 100 mg for patients ≥100 kg)
• Documentation that lifestyle modification (diet, exercise) was attempted or is ongoing
• Prescriber specialty or consultation note from a hepatologist/gastroenterologist

Processing time for MaineCare prior authorization typically ranges from 5 to 15 business days. Denials can be appealed within 60 days under MaineCare's fair hearing process. The CMS Medicaid guidelines require states to cover FDA-approved drugs for their approved indications, which provides a strong basis for appeal if an initial PA is denied.

Commercial insurers in Maine vary in their coverage policies. Anthem Blue Cross Blue Shield, Aetna, and Harvard Pilgrim have each issued medical policies on Rezdiffra, and most require similar documentation. Patients should request a benefits investigation through their prescriber's office or the specialty pharmacy before filling the prescription.

Madrigal Pharmaceuticals operates a patient support program called Madrigal Connect that assists with prior authorization paperwork and copay support. Eligible commercially insured patients may pay as little as $0 per month through the manufacturer's copay card, subject to annual caps.

Pharmacy Options in Maine: Specialty and 503A Compounding

Rezdiffra is distributed through specialty pharmacy channels. It is not stocked at standard retail pharmacies like CVS or Walgreens in most markets. Maine patients have two primary pharmacy pathways.

Specialty pharmacies with Rezdiffra distribution agreements handle the majority of prescriptions. These pharmacies manage the prior authorization process, coordinate with the prescriber, and ship directly to the patient's home. National specialty pharmacies with Maine shipping capability include Optum Specialty Pharmacy, Accredo, and CVS Specialty. Some Maine-based independent specialty pharmacies also carry the drug.

503A compounding pharmacies in Maine are licensed to compound and dispense resmetirom under physician prescription. Under FDA guidance on 503A compounding, these pharmacies prepare medications based on individual patient prescriptions and can ship within the state. Maine's Board of Pharmacy regulates 503A facilities and requires compliance with United States Pharmacopeia (USP) standards.

The distinction matters for cost. Brand-name Rezdiffra from a specialty pharmacy carries a wholesale acquisition cost (WAC) of approximately $47,400 per year. A compounded version from a 503A pharmacy may cost significantly less, though insurance coverage for compounded products varies and some payers will not cover them.

Delivery timelines in Maine depend on the pathway. Specialty pharmacy fulfillment typically takes 7 to 14 days from prescription receipt, including the PA process. If PA is already approved, shipment usually arrives within 3 to 5 business days. Compounding pharmacies may fill the prescription in 5 to 7 business days without the PA delay.

Dosing, Administration, and Monitoring on Rezdiffra

Rezdiffra dosing is weight-based per the FDA prescribing information. Patients weighing less than 100 kg take one 80 mg tablet once daily. Patients at or above 100 kg take one 100 mg tablet once daily. The tablet is taken by mouth with or without food.

There are no dietary restrictions specific to resmetirom, though patients with MASH are generally advised to follow a Mediterranean-pattern diet and engage in 150 minutes per week of moderate-intensity exercise per AASLD practice guidance.

Monitoring after initiation follows a structured schedule. Liver function tests should be checked at 12 weeks, then every 6 months during the first year. Thyroid function should be reassessed at 12 weeks. Lipid panels at 12 and 24 weeks help track the expected LDL and triglyceride reductions. FibroScan or equivalent imaging should be repeated at 12 months to assess treatment response.

The MAESTRO-NASH trial reported the most common adverse events as diarrhea (27% on 100 mg vs. 16% on placebo) and nausea (20% vs. 12%). Most GI effects were mild to moderate and resolved within the first 4 to 8 weeks of treatment. Serious adverse events occurred at similar rates in the resmetirom and placebo groups [1].

Discontinuation should be discussed with the prescriber. There is no established rebound effect, but MASH progression may resume without treatment. Patients who do not achieve MASH resolution or fibrosis improvement at 12 months should be reassessed for alternative or additional therapies.

Transferring a Rezdiffra Prescription to Maine

Patients relocating to Maine or visiting for extended periods can transfer an existing Rezdiffra prescription. Maine Board of Pharmacy regulations permit prescription transfers from other states for non-controlled substances. The process requires the originating pharmacy to contact the receiving Maine pharmacy to transfer the prescription record.

For specialty pharmacy patients, the transfer may involve switching to a specialty pharmacy with Maine dispensing authorization. Patients should contact their current specialty pharmacy and Madrigal Connect at least 2 weeks before the move to avoid gaps in medication supply.

Telehealth makes continuity straightforward. If the original prescriber holds a Maine license (or practices through a multistate telehealth platform with Maine coverage), they can continue managing the prescription without transferring care. If not, the patient will need to establish care with a Maine-licensed provider who can verify the existing MASH diagnosis and continue the prescription.

The Bigger Picture: MASH Treatment Access in Rural New England

Maine's geography creates real access challenges. The state has 1.39 million residents spread across 35,385 square miles, with population density among the lowest on the East Coast. Subspecialty hepatology is concentrated in Portland and Bangor. A 2023 analysis in Hepatology estimated that 42% of rural Americans with advanced liver disease live more than 50 miles from a hepatologist.

Rezdiffra's oral, once-daily formulation makes it well suited for remote management. There are no injections, no infusion centers, and no required in-office administration. A patient in Presque Isle or Calais can receive the same standard of care as a patient in Portland, provided they have access to baseline lab work and elastography.

The combination of Maine's telehealth-permissive laws, 503A pharmacy licensing, and Medicaid coverage with PA creates a functional access pathway even for patients in the state's most remote counties. The bottleneck is diagnosis, not distribution. An estimated 80% of MASH cases remain undiagnosed nationally according to a 2023 analysis in the Journal of Hepatology, and Maine is unlikely to be an exception [2].

Clinicians in Maine should consider screening patients with obesity (BMI ≥30), type 2 diabetes, or metabolic syndrome using the FIB-4 index (a simple calculation from age, AST, ALT, and platelet count). A FIB-4 score above 1.3 warrants referral for elastography. This two-step screening approach, endorsed by the American Gastroenterological Association, can identify Rezdiffra-eligible patients who would otherwise go unrecognized [3].

Rezdiffra 80 mg for a patient weighing 88 kg: one tablet daily by mouth, with repeat FibroScan at 12 months and LFTs at 12 weeks.